MaltSci 麦伴科研

Appearance

Popular Reports / Neuroscience

This report is written by MaltSci based on the latest literature and research findings

What are the neural mechanisms of depression? ​

Abstract ​

Depression is a prevalent mental health disorder with a complex neurobiological basis characterized by heterogeneous symptomatology, including persistent sadness, anhedonia, and cognitive dysfunction. Recent advancements in neuroimaging and molecular biology have illuminated the structural and functional alterations in the brains of individuals with depression. This report systematically explores the neural mechanisms underlying depression, focusing on neuroanatomy, neurotransmitter systems, neuroplasticity, and the influence of genetic and environmental factors. Key findings highlight the critical roles of the prefrontal cortex, amygdala, and hippocampus in emotional regulation, with dysregulation in serotonergic, dopaminergic, and noradrenergic systems contributing to the disorder. Furthermore, the interplay between genetic predispositions and environmental stressors, particularly early life stress, shapes individual vulnerability to depression. Therapeutic implications are discussed, emphasizing the need for targeted interventions that extend beyond traditional pharmacological approaches to include psychotherapeutic and lifestyle strategies. The insights gained from this investigation underscore the urgency for continued research into the neurobiological underpinnings of depression to inform effective treatment and intervention strategies.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Neuroanatomy of Depression
    • 2.1 The Role of the Prefrontal Cortex
    • 2.2 The Amygdala and Emotional Processing
    • 2.3 Hippocampal Function and Neurogenesis
  • 3 Neurotransmitter Systems Involved in Depression
    • 3.1 Serotonergic System
    • 3.2 Dopaminergic System
    • 3.3 Noradrenergic System
  • 4 Neuroplasticity and Depression
    • 4.1 Structural Changes in the Brain
    • 4.2 Functional Connectivity Alterations
    • 4.3 The Impact of Stress on Neuroplasticity
  • 5 Genetic and Environmental Influences
    • 5.1 Genetic Predisposition to Depression
    • 5.2 The Role of Early Life Stress
    • 5.3 Interaction Between Genetics and Environment
  • 6 Therapeutic Implications
    • 6.1 Pharmacological Treatments
    • 6.2 Psychotherapy and Behavioral Interventions
    • 6.3 Future Directions in Treatment Approaches
  • 7 Summary

1 Introduction ​

Depression is a pervasive mental health disorder that affects millions globally, leading to significant impairment in daily functioning and quality of life. The complexity of depression is reflected in its heterogeneous symptomatology, which ranges from persistent sadness and anhedonia to cognitive dysfunction and emotional dysregulation. Understanding the neural mechanisms underlying depression is essential for developing effective treatments and interventions. Recent advancements in neuroimaging and molecular biology have begun to illuminate the structural and functional changes in the brains of individuals suffering from depression, thereby providing insights into its neurobiological basis [1][2].

The significance of exploring the neural mechanisms of depression cannot be overstated. With an increasing prevalence of depression worldwide, there is an urgent need for targeted therapeutic strategies that go beyond traditional pharmacological approaches. By elucidating the neuroanatomical and neurochemical alterations associated with depression, researchers can identify novel biomarkers and therapeutic targets that could lead to more effective treatments [3][4]. Furthermore, understanding the interplay between genetic predispositions, environmental stressors, and neurobiological changes can inform preventive measures and early interventions, ultimately improving patient outcomes [5][6].

Current research has shifted from a simplistic view of depression as a mere chemical imbalance to a more nuanced understanding that incorporates neural circuitry, neuroplasticity, and the role of neurotransmitter systems [6][7]. Studies have shown that alterations in key brain regions, such as the prefrontal cortex, amygdala, and hippocampus, are implicated in the pathophysiology of depression. These regions are critical for emotional processing, memory formation, and the regulation of stress responses [8][9]. Moreover, emerging evidence suggests that changes in synaptic plasticity and neurogenesis may contribute to the onset and persistence of depressive symptoms [4][10].

This report is organized into several key sections that will systematically address the neurobiological underpinnings of depression. The first section will delve into the neuroanatomy of depression, highlighting the roles of the prefrontal cortex, amygdala, and hippocampus in emotional regulation and cognitive function. The subsequent section will examine the neurotransmitter systems involved in depression, including the serotonergic, dopaminergic, and noradrenergic systems, and their impact on mood and behavior. Following this, we will explore the concept of neuroplasticity in depression, discussing structural and functional changes in the brain, as well as the effects of stress on neural adaptability.

In addition, we will investigate the genetic and environmental influences on depression, emphasizing how genetic predispositions and early life stressors interact to shape individual vulnerability to the disorder. The report will also address therapeutic implications, reviewing current pharmacological treatments and psychotherapeutic approaches, as well as highlighting potential future directions in treatment strategies.

By synthesizing current research findings, this report aims to provide a comprehensive overview of the neural mechanisms underlying depression, emphasizing the need for continued exploration in this critical area of mental health research. The insights gained from this investigation may not only advance our understanding of depression but also pave the way for innovative therapeutic interventions that can effectively address this debilitating disorder.

2 Neuroanatomy of Depression ​

2.1 The Role of the Prefrontal Cortex ​

Depression is a complex neuropsychiatric disorder characterized by persistent low mood and anhedonia, significantly impacting individual health and quality of life. The neural mechanisms underlying depression are multifaceted, with a central focus on the prefrontal cortex (PFC), which plays a critical role in emotional and cognitive regulation.

The prefrontal cortex, particularly the medial prefrontal cortex (mPFC), is implicated in the pathophysiology of depression through its involvement in self-appraisal processes and emotion regulation. A study by Davey et al. (2017) demonstrated that in individuals with major depressive disorder, the mPFC exhibits a "hyperregulatory" effect on the posterior cingulate cortex during self-directed cognitive processes. This abnormal modulation leads to significantly more negative connectivity, correlating with symptoms such as poor concentration and inner tension [11].

Neurotransmitter systems within the PFC are crucial in mediating depressive symptoms. Dopamine (DA), serotonin (5-HT), and gamma-aminobutyric acid (GABA) play significant roles in modulating neural circuits associated with reward processing, cognitive functions, and emotional regulation. Dysregulation of these neurotransmitters has been linked to altered excitability of PFC pyramidal neurons, contributing to the pathogenesis of depression. For instance, Li et al. (2025) highlighted that reduced DA and 5-HT levels exacerbate emotional disturbances, while GABA dysfunction leads to excessive excitation in PFC circuits [12].

Moreover, computational modeling studies have revealed that abnormalities in coupling relationships within the prefrontal-cingulate cortex networks can disturb the balance between emotion and cognition, further contributing to the development of depression [13]. This imbalance is believed to stem from diminished inhibitory control, leading to increased intrusive rumination and impaired emotional regulation [14].

Neuroimaging studies have also shown structural and functional alterations in the PFC in individuals with depression. Rigucci et al. (2010) noted that changes in grey matter volume and neurophysiological activity in the medial prefrontal network, amygdala, and hippocampus are prevalent in recurrent depressive episodes, emphasizing the importance of these regions in emotional behavior modulation [15]. Additionally, alterations in the effective connectivity between the PFC and amygdala have been associated with the severity of depressive symptoms [16].

In summary, the prefrontal cortex is central to the neural mechanisms of depression, with its dysfunction manifesting through altered neurotransmitter activity, impaired connectivity with limbic structures, and structural changes. These insights underscore the complexity of depression and the need for targeted interventions that address the specific neurobiological pathways involved. Future research should continue to explore these mechanisms to enhance the understanding and treatment of depression.

2.2 The Amygdala and Emotional Processing ​

The amygdala plays a crucial role in the neural mechanisms underlying depression, particularly in the context of emotional processing. It is an evolutionarily conserved structure that is integral to emotion regulation and is part of a cortico-limbic circuitry implicated in various affective disorders. Research has shown that abnormalities in amygdala function and connectivity are associated with the pathophysiology of depression.

Neuroimaging studies have highlighted the heterogeneous nature of the amygdala, which is composed of functionally and neuroanatomically distinct subnuclei. For instance, ultra-high-field imaging has demonstrated that this advanced imaging technique provides more accurate representations of the amygdala's functional and structural properties, as well as its connectivity with other brain regions involved in emotion processing (Kirstein et al., 2023) [17]. These studies indicate that individuals with major depression often exhibit rightward amygdala atrophy or distinct bilateral patterns of subnuclear atrophy and hypertrophy.

Functional connectivity analyses reveal that the amygdala is part of widespread networks involved in learning, memory, cognition, and social processes. Specific roles have been identified for different amygdala nuclei in fear and emotion processing, suggesting that disruptions in these circuits may contribute to the emotional dysregulation seen in depression (Kirstein et al., 2023) [17].

Moreover, genetic factors have been implicated in amygdala connectivity and function. For example, research has shown that carriers of certain alleles of the monoamine oxidase A gene (MAOA) exhibit reduced amygdala-prefrontal coupling, which is significantly associated with the severity of major depression. This reduced connectivity may contribute to the longer and more severe courses of the illness (Dannlowski et al., 2009) [18]. Similarly, variations in the serotonin transporter gene (5-HTTLPR) have been linked to increased amygdala reactivity to emotional stimuli, indicating a potential pathway through which genetic predispositions can influence the risk of chronic depression (Dannlowski et al., 2008) [19].

In addition to structural and functional abnormalities, the amygdala's hyperactivity in response to emotional stimuli has been observed in untreated depressed individuals. Studies have shown that depressed patients display sustained amygdala responses to negative emotional information, which correlates with rumination and emotional dysregulation (Siegle et al., 2002) [20]. This hyperactivation reflects a tendency for prolonged elaborative processing of negative emotional stimuli, further exacerbating depressive symptoms.

The amygdala's role extends beyond emotional reactivity to include its interaction with other brain regions, such as the prefrontal cortex and hippocampus. These interactions are critical for the regulation of emotions and memory. For instance, the amygdala and hippocampus work synergistically to form long-term emotional memories, and disruptions in this circuitry can lead to the emotional and cognitive deficits commonly seen in depression (Yang & Wang, 2017) [21].

Overall, the neural mechanisms of depression, particularly concerning the amygdala, involve a complex interplay of structural, functional, and genetic factors that influence emotional processing and regulation. Understanding these mechanisms is essential for developing targeted therapeutic strategies for individuals suffering from depression.

2.3 Hippocampal Function and Neurogenesis ​

Depression is a multifaceted disorder characterized by alterations in neural circuitry and neurogenesis, particularly within the hippocampus. The hippocampus, a critical region involved in memory and emotional regulation, exhibits significant changes in function and structure in individuals suffering from depression. This review synthesizes current understanding regarding the neural mechanisms underlying depression, with a particular focus on hippocampal function and neurogenesis.

The neurogenesis hypothesis of depression posits that reduced neurogenesis in the hippocampus contributes to the pathophysiology of depression. Neurogenesis, the process of generating new neurons, is particularly prominent in the dentate gyrus of the hippocampus and is influenced by various factors including stress, neuroinflammation, and neurotrophic factors. Studies have shown that depression is associated with reduced hippocampal volume and activity, which correlates with impaired neurogenesis and is linked to depression-related behaviors in both humans and animal models[9][22].

Research indicates that neurogenesis is an activity-dependent process; thus, disruptions in neural circuitry can lead to impairments in neurogenesis observed in depression. The entorhinal cortex plays a pivotal role in regulating hippocampal neurogenesis and is implicated in the cognitive and emotional phenotypes associated with depression. However, the exact mechanisms by which alterations in neural circuitry affect neurogenesis in depression remain to be fully elucidated[22].

Chronic stress, a major environmental risk factor for depression, adversely affects hippocampal neurogenesis through mechanisms involving neuroinflammation and microglial activation. Microglia, the resident immune cells of the central nervous system, have been shown to influence neurogenesis by modulating inflammatory responses, which can lead to either neuroprotection or neurodegeneration depending on their activation state[23][24]. This relationship suggests that changes in microglial status may underlie neurogenesis impairments and contribute to the development of depressive-like behaviors[23].

Antidepressant treatments, particularly those that promote neurogenesis, have been found to enhance hippocampal function and alleviate symptoms of depression. For instance, selective serotonin reuptake inhibitors (SSRIs) have been shown to increase neurogenesis in the hippocampus, suggesting a link between neurogenic processes and the therapeutic effects of antidepressants[25][26]. However, the neurogenesis hypothesis remains debated, as some studies indicate that while neurogenesis may play a role in the efficacy of antidepressants, it is not the sole mechanism involved in the complex neurobiology of depression[27].

In conclusion, the interplay between neural circuitry, hippocampal function, and neurogenesis is crucial in understanding the pathophysiology of depression. Ongoing research into the mechanisms governing these processes may yield new insights and therapeutic strategies aimed at enhancing neurogenesis and restoring hippocampal function in individuals suffering from depression. The multi-target approach of traditional Chinese medicine and other emerging therapies holds promise for further exploration in this context[28].

3 Neurotransmitter Systems Involved in Depression ​

3.1 Serotonergic System ​

The serotonergic system plays a crucial role in the pathophysiology of depression, which is a complex neuropsychiatric disorder. This system, characterized by serotonergic neurons that release serotonin (5-HT), is involved in regulating various physiological and psychological functions, including mood, cognition, anxiety, and sleep. Dysregulation within this system has been implicated in the development of depressive symptoms.

The serotonergic system's dysfunction can be traced to several neurobiological mechanisms. One significant aspect is the relationship between serotonin levels and mood regulation. Research indicates that depression is associated with a functional decrease in serotonergic neurotransmission, which correlates with specific alterations in sleep patterns, particularly insomnia. Interestingly, while depressed patients often report sleep loss, they may experience mood improvement after a night of sleep deprivation, suggesting that sleep loss might trigger compensatory neurobiological mechanisms that enhance serotonergic activity (Adrien 2002).

The serotonin transporter (SERT) is a key regulator of serotonin levels in the brain and is a primary target for antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs). However, the efficacy of SSRIs can vary, leading to the exploration of other mechanisms that may contribute to depression. For instance, evidence suggests that increased inflammation and oxidative stress can significantly impact serotonergic function, leading to neuroprogression characterized by neurodegeneration and impaired neurogenesis (Bansal et al. 2019).

Moreover, the interaction between the serotonergic system and inflammatory processes is noteworthy. Pro-inflammatory cytokines can modulate SERT function, thus affecting serotonin signaling and contributing to the development of depressive symptoms. This highlights a potential interplay between serotonergic neurotransmission and the immune system, suggesting that neuroinflammation may play a role in the etiology of depression (Haase & Brown 2015).

In addition to the direct effects of serotonin, the serotonergic system also influences other neurotransmitter systems, such as noradrenergic and dopaminergic systems. This interconnectedness suggests that alterations in serotonin signaling may lead to changes in the activity of these other systems, further complicating the neurobiology of depression (Gorman & Sullivan 2000).

Furthermore, chronic stress and serotonergic denervation can lead to long-term changes in neuronal oxidative metabolism, indicating that stress-related alterations in serotonergic function may exacerbate depressive symptoms (Kanarik et al. 2008). The role of oxidative stress, particularly the presence of hydrogen peroxide, has been highlighted as a factor that disrupts serotonergic neuron function, suggesting that oxidative damage may contribute to the pathophysiology of depression (Che et al. 2024).

Overall, the serotonergic system's involvement in depression is multifaceted, encompassing neurotransmitter regulation, neuroinflammatory processes, and interactions with other neurochemical systems. This complexity underscores the need for a comprehensive understanding of the serotonergic system to develop more effective therapeutic strategies for treating depression.

3.2 Dopaminergic System ​

The dopaminergic system plays a critical role in the pathophysiology of depression, with emerging evidence highlighting its involvement in various aspects of depressive symptoms, particularly anhedonia and motivation deficits. The complexity of major depressive disorder (MDD) suggests that the neural substrates are multifaceted, and the dopaminergic pathways are essential components of this intricate network.

The mesolimbic dopamine pathway, which is primarily associated with reward processing, has been linked to the experience of anhedonia—a core symptom of depression. A review by Pannu and Goyal (2025) discusses how the mesolimbic pathway's dysfunction may contribute to this symptom, emphasizing its significance in mood regulation, cognitive function, and motivation [29]. Specifically, alterations in dopaminergic activity within this circuit are associated with diminished responses to rewarding stimuli, suggesting that individuals with depression may exhibit a blunted reaction to positive reinforcers [30].

In addition to the mesolimbic pathway, the mesocortical dopamine pathway, which projects to the prefrontal cortex, is implicated in cognitive symptoms such as impaired attention and decision-making. This pathway's dysfunction can exacerbate the cognitive deficits often observed in depressed patients [29]. Furthermore, the nigrostriatal pathway, responsible for motor control, is associated with psychomotor retardation in depression, highlighting the diverse roles that dopaminergic circuits play in the overall symptomatology of the disorder [29].

The role of the dopamine D3 receptor subtype has garnered attention as a potential pharmacological target in treating depression. This receptor is implicated in motivation and reward-related behaviors and has been shown to be down-regulated in states of stress and depression. Antidepressant treatments have been observed to reverse these changes, suggesting that enhancing dopaminergic neurotransmission via D3 receptors could be beneficial in ameliorating depressive symptoms [31].

Moreover, the reciprocal interactions between the dopaminergic system and other neurotransmitter systems, such as serotonergic and adrenergic systems, further complicate the neurobiological landscape of depression. The monoamine hypothesis, which posits that depression is primarily due to deficiencies in serotonin and norepinephrine, has been expanded to include the critical roles of dopamine in mood regulation [32].

Neuroimaging studies have demonstrated decreased activity in brain reward circuits in individuals with major depression, underscoring the relevance of dopaminergic pathways in the manifestation of depressive symptoms [33]. These findings support the notion that targeting the dopaminergic system may offer new therapeutic avenues, particularly for patients who exhibit treatment resistance to conventional antidepressants that primarily affect serotonin and norepinephrine [29].

In summary, the dopaminergic system's involvement in depression is multifaceted, influencing reward processing, motivation, and cognitive function. The dysfunction of various dopaminergic pathways contributes significantly to the symptomatology of major depressive disorder, and ongoing research continues to explore these mechanisms to develop more effective treatment strategies.

3.3 Noradrenergic System ​

The noradrenergic system plays a critical role in the pathophysiology of depression, with extensive evidence suggesting its dysfunction is implicated in various depressive disorders. Research indicates that abnormalities in norepinephrine (NE) neurotransmission contribute significantly to the symptomatology of depression and anxiety disorders. Specifically, there is a consistent pattern of underactivation of serotonergic function coupled with a complex dysregulation of noradrenergic function, often characterized by overactivation of the noradrenergic system [34].

Chronic stress has been identified as a significant factor leading to dysregulation of the noradrenergic system, which is linked to the development of major depressive disorder (MDD). The lack of monoamines, including norepinephrine, in the brain is traditionally viewed as a primary causative factor in the pathophysiology of MDD. Various antidepressants function by increasing monoamine levels at synapses, which may include enhancing noradrenergic transmission [35]. However, the exact role of noradrenergic receptor stimulation in the therapeutic effects of antidepressants remains a subject of investigation. It has been proposed that the desensitization of β-adrenoceptors may be more critical for the therapeutic efficacy of these medications [35].

Furthermore, the interaction between noradrenergic and serotonergic systems is vital. Stimulation of one system can lead to effects in the other, indicating a complex interplay that may influence the clinical efficacy of various antidepressants [36]. Atypical antidepressants that exhibit mixed serotonergic and noradrenergic effects or those that primarily target the noradrenergic system, such as selective norepinephrine reuptake inhibitors (NARIs), have shown clinical efficacy [37].

Research has also highlighted that noradrenergic dysfunction may affect various brain regions and circuits involved in mood regulation. For instance, disrupted cortical regulation is linked to impaired concentration and memory, while hypothalamic abnormalities can contribute to altered appetite and libido. Dysregulation in thalamic and brainstem areas may influence sleep and arousal states [34]. Additionally, increased activity of locus coeruleus (LC) neurons, which are the principal norepinephrine-containing cells in the brain, may lead to symptoms such as decreased motor activation and anhedonia, thereby reinforcing the association between noradrenergic dysfunction and depressive behaviors [38].

Overall, the noradrenergic system's involvement in depression underscores the importance of understanding its role in the broader context of neurobiological mechanisms underlying affective disorders. The dysregulation of this system, along with its interaction with other neurotransmitter systems, remains a key area of focus for developing effective treatment strategies for depression [39].

4 Neuroplasticity and Depression ​

4.1 Structural Changes in the Brain ​

Depression is associated with significant structural changes in various brain regions, particularly those involved in mood regulation and cognitive function, such as the hippocampus, prefrontal cortex, and amygdala. These alterations in neural architecture are primarily linked to disruptions in neuroplasticity, which is the brain's ability to adapt functionally and structurally to environmental stimuli.

Neuroplasticity encompasses several processes, including neurogenesis (the generation of new neurons), synaptogenesis (the formation of new synapses), and changes in dendritic structure. In individuals suffering from depression, these processes are often impaired. For instance, studies indicate that chronic stress, a major precipitating factor for depression, leads to dendritic atrophy in the hippocampus and prefrontal cortex, characterized by reduced dendritic branching and spine density, ultimately contributing to cognitive deficits and emotional dysregulation [40][41].

Moreover, the amygdala exhibits increased dendritic branching and altered neuronal size, reflecting its heightened activity in response to stress and emotional stimuli in depressed individuals [40]. The prefrontal cortex also shows reduced glial cell density and neuronal size, which may further exacerbate the symptoms of depression [41].

At the molecular level, the neurotrophic/plasticity hypothesis of depression posits that alterations in the levels of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF), play a crucial role in these structural changes. BDNF is vital for supporting the survival of existing neurons and promoting neurogenesis and synaptic plasticity. In depressed patients, reduced BDNF levels have been correlated with decreased neurogenesis and impaired synaptic functioning, contributing to the pathophysiology of the disorder [42][43].

Furthermore, the immune system has been implicated in the neuroplastic changes associated with depression. Chronic inflammation and elevated levels of pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factor-alpha, can disrupt neuroplasticity by affecting neurogenesis and synaptic function [44]. This interaction suggests that both neuroimmune mechanisms and neuroplasticity are integral to understanding the structural and functional deficits observed in depression [44][45].

In summary, the neural mechanisms of depression are characterized by significant structural changes in key brain regions, driven by impairments in neuroplasticity. These changes manifest as dendritic atrophy, reduced neurogenesis, and altered glial function, with critical contributions from neurotrophic factors and immune responses. Understanding these mechanisms not only elucidates the pathophysiology of depression but also highlights potential therapeutic targets for intervention [40][41][45].

4.2 Functional Connectivity Alterations ​

The neural mechanisms of depression are complex and multifaceted, primarily involving disruptions in neuroplasticity and alterations in functional connectivity within various brain regions. Neuroplasticity refers to the brain's ability to adapt structurally and functionally in response to experiences and environmental changes. In the context of depression, neuroplasticity is often impaired, which contributes to the pathophysiology of the disorder.

One of the key features of depression is the alteration of neurotransmitter systems, particularly the monoaminergic system, which includes serotonin, norepinephrine, and dopamine. These neurotransmitters play crucial roles in mood regulation, and their dysregulation is closely associated with depressive symptoms. In addition to neurotransmitter changes, structural and functional alterations in specific brain regions, such as the hippocampus, prefrontal cortex, and amygdala, have been observed in depressed individuals.

The hippocampus is particularly significant in the study of depression due to its role in memory and learning. In depression, there is evidence of reduced neurogenesis (the formation of new neurons), dendritic atrophy, and decreased hippocampal volume, which may lead to cognitive deficits and emotional disturbances. Tianeptine, an antidepressant, has been shown to reverse some of these structural changes by enhancing neurogenesis and normalizing glutamatergic neurotransmission, thereby improving neuroplasticity in the hippocampus [40].

Furthermore, the prefrontal cortex, responsible for executive functions and emotional regulation, exhibits reduced neuronal size and glial cell density in depressed individuals. This reduction can impair cognitive function and emotional responses, contributing to the symptoms of depression [40]. In contrast, the amygdala often shows increased dendritic branching, which may reflect heightened emotional responses and anxiety associated with depression [40].

Functional connectivity alterations are also critical in understanding the neural mechanisms of depression. Studies using neuroimaging techniques have demonstrated abnormal connectivity patterns between brain regions involved in emotional processing and regulation. For instance, depressed patients often exhibit disrupted connectivity between the prefrontal cortex and the amygdala, which may underlie the impaired regulation of emotional responses and heightened sensitivity to stress [46]. Transcranial magnetic stimulation (TMS) studies have indicated that depressed individuals show significant differences in motor cortex excitability and imbalances in inhibitory and excitatory neurotransmission, further highlighting the disrupted plasticity and connectivity in the brain [46].

Additionally, the neuroimmune system has been implicated in the neuroplastic changes associated with depression. Factors such as interleukins and tumor necrosis factor (TNF)-α can negatively impact neuroplasticity by influencing neurogenesis and synaptic functioning [44]. The interplay between neuroinflammation and neuroplasticity suggests that immune responses may exacerbate the neurobiological alterations seen in depression.

In summary, the neural mechanisms of depression involve a combination of impaired neuroplasticity, alterations in neurotransmitter systems, structural changes in key brain regions, and disruptions in functional connectivity. These mechanisms collectively contribute to the cognitive and emotional deficits observed in depression, emphasizing the need for targeted therapeutic strategies that address these underlying neurobiological processes. Understanding these mechanisms may pave the way for the development of more effective treatments that enhance neuroplasticity and restore normal brain function in individuals with depression [40][44][46].

4.3 The Impact of Stress on Neuroplasticity ​

Neuroplasticity, defined as the brain's ability to adapt functionally and structurally in response to stimuli, plays a crucial role in the pathophysiology of depression. Research indicates that neuroplasticity is significantly disrupted in individuals suffering from mood disorders, particularly under the influence of chronic stress. Stress is known to precipitate or exacerbate depressive symptoms, and its impact on neuroplasticity can manifest through various mechanisms.

Chronic stress has been shown to induce detrimental changes in neuroplasticity, particularly within key brain regions such as the hippocampus and prefrontal cortex. These changes include reductions in the proliferation of neural stem cells, decreased survival of neuroblasts, impaired neurocircuitry, and alterations in synaptic plasticity. Specifically, structural changes like dendritic atrophy, reduced dendritic spine density, and decreased levels of neurotrophic factors have been observed in these regions, which correlate with the cognitive and emotional impairments associated with depression [44][45].

Moreover, the immune system appears to interact with neuroplastic processes during episodes of stress and depression. Neuroimmune factors, including pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), have been implicated in the impairment of neuroplasticity. These factors can influence processes such as long-term potentiation (LTP), neurogenesis, and the survival of neural cells, thereby exacerbating the effects of stress on the brain [44].

The modulation of neuroplasticity through pharmacological interventions has garnered attention as a potential therapeutic strategy for depression. Antidepressant treatments, including the administration of ketamine and traditional antidepressants, have been found to enhance neuroplasticity, promoting synaptic formation and improving neuronal survival. These treatments counteract the negative effects of stress on neuroplasticity and can lead to improved mood and cognitive function [43][47].

In summary, the neural mechanisms underlying depression are closely linked to disruptions in neuroplasticity driven by stress. The interplay between neuroplastic changes and the immune response highlights the complexity of depression's pathophysiology and underscores the importance of targeting these mechanisms in developing effective treatments. Further understanding of these processes may pave the way for novel therapeutic approaches aimed at restoring neuroplasticity and alleviating depressive symptoms.

5 Genetic and Environmental Influences ​

5.1 Genetic Predisposition to Depression ​

Depression, particularly major depressive disorder (MDD), is characterized by a complex interplay of genetic and environmental factors that contribute to its pathogenesis. The neural mechanisms underlying depression are influenced significantly by both genetic predispositions and environmental stressors, which can alter brain function and structure.

Genetic factors play a crucial role in the susceptibility to depression. Studies have indicated that the heritability rate for depression is approximately 37%, suggesting a substantial genetic contribution to the disorder (Jindal et al. 2024). Genetic variations have been identified that correlate with an increased risk of developing depression, highlighting the importance of specific genetic polymorphisms in this context (Zhang et al. 2023). For instance, variations in genes associated with serotonin transport, such as the serotonin transporter-linked promoter region (5-HTTLPR), have been shown to interact with environmental factors like childhood adversity, thereby influencing the risk of depression (Kim et al. 2019).

Moreover, neuroimaging studies have elucidated structural and functional abnormalities in brain regions associated with mood regulation, such as the amygdala, prefrontal cortex, and hippocampus, in individuals with depression. These regions are crucial for processing emotional information and regulating responses to stress (Gold & Wong 2025). The interaction between genetic predispositions and environmental stressors can lead to alterations in neurotrophic factors, serotonergic neurotransmission, and the hypothalamus-pituitary-adrenal (HPA) axis, which are all implicated in the development of depressive symptoms (Uchida et al. 2018).

Environmental factors, particularly stress, significantly modulate the risk of developing depression. Stressful life events, including childhood adversity, have been associated with lasting changes in gene expression that may lead to maladaptive neuronal plasticity (Penner-Goeke & Binder 2019). Epigenetic mechanisms, such as DNA methylation and histone modifications, can mediate these effects by altering gene expression without changing the underlying DNA sequence. For example, exposure to chronic stress has been shown to induce epigenetic changes that affect stress response pathways and neuronal function, contributing to the pathophysiology of depression (Bagot et al. 2014; Rusconi & Battaglioli 2018).

Furthermore, the interaction between genetic predispositions and environmental factors is complex. While certain genetic variations may confer vulnerability to depression, the presence of protective environmental factors can mitigate this risk. Conversely, adverse environmental conditions can exacerbate genetic vulnerabilities, leading to an increased likelihood of developing depressive disorders (Northoff 2013; Alshaya 2022).

In summary, the neural mechanisms of depression are deeply rooted in the interplay between genetic and environmental influences. Genetic predispositions, particularly those affecting neurotransmitter systems and stress response pathways, interact with environmental stressors to shape the neurobiological landscape of depression. Understanding these mechanisms is critical for developing targeted therapeutic interventions that address both genetic and environmental factors contributing to this complex disorder.

5.2 The Role of Early Life Stress ​

Depression is a multifaceted psychiatric disorder characterized by various neural mechanisms influenced by both genetic and environmental factors. A significant body of research highlights the critical role of early life stress (ELS) in shaping the neurobiological underpinnings of depression.

Early life stress is established as a major risk factor for developing depressive disorders later in life. Studies indicate that experiences such as childhood abuse, neglect, and loss can lead to long-lasting changes in the brain's neurobiological systems, heightening vulnerability to depression. These changes are not merely the result of genetic predispositions but also involve complex interactions between genetic and environmental influences, often referred to as gene-environment interactions (G×E) [48].

The neurobiological mechanisms by which ELS contributes to depression involve alterations in the hypothalamic-pituitary-adrenal (HPA) axis, neurotransmitter systems, and epigenetic modifications. The HPA axis, which regulates stress responses, is particularly sensitive to early adverse experiences. ELS can lead to dysregulation of this system, resulting in heightened reactivity to stress and increased levels of corticotropin-releasing factor (CRF), which has been implicated in the pathogenesis of depression [49].

Furthermore, ELS is associated with epigenetic changes that affect gene expression without altering the underlying DNA sequence. These changes can include DNA methylation, histone modifications, and alterations in non-coding RNAs, which collectively influence the transcriptional activity of genes involved in neuroplasticity and stress response [50]. For instance, epigenetic modifications can lead to decreased expression of glucocorticoid receptors, impaired serotonin production, and reduced neurogenesis and neuroplasticity, all of which are crucial for maintaining emotional regulation and resilience against stress [51].

Research also suggests that different types of ELS can induce specific epigenetic modifications that affect neurotransmitter systems, including the dopaminergic, serotonergic, GABAergic, and glutamatergic systems. These neurotransmitter systems are essential for mood regulation, and their dysregulation is often observed in individuals with depression [52]. The interplay between these neurotransmitter systems and the epigenetic landscape created by ELS highlights the complexity of depression's neurobiological basis.

Moreover, it is essential to consider the developmental context in which ELS occurs. The impact of early adversity on neurobiological systems may vary depending on the timing of the stressor, as certain sensitive periods in brain development may render individuals more susceptible to the adverse effects of stress [53]. This perspective emphasizes the need for targeted interventions that address the specific vulnerabilities associated with early life experiences.

In conclusion, the neural mechanisms of depression are intricately linked to both genetic predispositions and environmental factors, particularly early life stress. The dysregulation of the HPA axis, neurotransmitter systems, and epigenetic modifications collectively contribute to the pathophysiology of depression, underscoring the importance of understanding these mechanisms for developing effective therapeutic strategies. Future research should continue to explore these complex interactions to identify potential biomarkers and novel interventions for depression.

5.3 Interaction Between Genetics and Environment ​

Depression, particularly major depressive disorder (MDD), is a complex psychiatric condition characterized by various behavioral changes and alterations in brain regions. The interplay between genetic and environmental factors significantly contributes to its etiology. Genetic predispositions and environmental stressors interact to modulate neural activity and behavior, ultimately influencing clinical symptoms.

Research indicates that specific genetic factors, particularly those related to neurotransmitter systems such as serotonin, play a critical role in the neural mechanisms underlying depression. For instance, genes that influence serotonin pathways have been shown to affect emotion-related neural activity in key brain regions, including the amygdala and the anterior cingulate cortex [54]. This highlights the importance of genetic factors in shaping neural responses to emotional stimuli.

Furthermore, the influence of environmental factors, particularly early life stress, has been extensively studied. Early adversity can lead to significant structural changes in brain regions associated with emotion regulation, such as the hippocampus and prefrontal cortex [55]. These structural alterations are often mediated by interactions with genetic factors, such as polymorphisms in genes like BDNF and the serotonin transporter gene (5-HTTLPR), which have been shown to interact with childhood adversity to affect brain morphology and increase the risk of developing depression [55].

Epigenetic mechanisms also play a crucial role in the interaction between genetics and environment in depression. These mechanisms include DNA methylation and histone modifications, which can alter gene expression without changing the underlying DNA sequence. Environmental stressors can induce epigenetic changes that affect stress response pathways and neuronal plasticity, contributing to the pathogenesis of depression [56].

Moreover, studies suggest that gene-environment interactions are pivotal in understanding individual vulnerabilities to depression. For example, the impact of specific genetic polymorphisms on depression risk can vary significantly depending on the level of environmental stress exposure [57]. This highlights the necessity of considering both genetic predispositions and environmental contexts when examining the neural mechanisms of depression.

The intergenerational transmission of depression risk further exemplifies the interaction between genetic and environmental influences. Parental depression has been identified as a significant risk factor for depression in offspring, with mechanisms involving both familial genetic predispositions and environmental factors, such as parenting styles and exposure to stress [58]. These findings underscore the complexity of depression's etiology, suggesting that both genetic and environmental factors are integral to understanding its neural underpinnings.

In summary, the neural mechanisms of depression are shaped by a dynamic interplay of genetic and environmental influences. Genetic factors contribute to individual vulnerabilities and brain function, while environmental stressors can lead to structural and functional changes in the brain. The integration of genetic and epigenetic research with environmental studies is crucial for advancing our understanding of depression and developing targeted interventions.

6 Therapeutic Implications ​

6.1 Pharmacological Treatments ​

Depression is a complex and heterogeneous mood disorder that is influenced by a multitude of neural mechanisms. Recent research has shifted the understanding of depression from solely focusing on neurotransmitter imbalances to a broader perspective that includes neurogenesis, neuroprotection, and the integrity of neural networks. The neurogenesis hypothesis of depression posits that changes in the rate of neurogenesis are a fundamental mechanism underlying the pathology and treatment of major depression. Factors such as stress, neuroinflammation, dysfunctional insulin regulation, oxidative stress, and alterations in neurotrophic factors contribute to the development of depression (Bewernick & Schlaepfer, 2013) [5].

The mechanisms of depression also involve significant alterations in brain connectivity and neuronal function. Chronic stress exposure has been shown to cause atrophy of neurons in key brain regions associated with depression, leading to disrupted connectivity within neural circuits that regulate emotions. Studies have identified deficits in both excitatory glutamate neurons and inhibitory GABA interneurons, which may compromise signal integrity in cortical and hippocampal regions (Duman et al., 2019) [59]. This dysfunction can be exacerbated by elevated levels of adrenal glucocorticoids and inflammatory cytokines, indicating a strong link between stress and depression (Duman et al., 2019) [59].

Pharmacological treatments for depression have traditionally focused on correcting neurotransmitter imbalances, particularly involving serotonin, norepinephrine, and dopamine. However, the efficacy of these treatments is often limited by adverse side effects and delayed therapeutic onset. Recent advances have led to the development of rapid-acting agents that target the glutamate and GABA systems, which show promise in providing quicker relief from depressive symptoms (Duman et al., 2019) [59].

In addition to conventional pharmacotherapy, there is growing interest in the role of botanical medicines in modulating depression. Recent reviews have highlighted the potential of herbal antidepressants to target various pathological mechanisms, including inflammation, oxidative stress, and neurogenesis, thereby offering a multifaceted approach to treatment (Zhang et al., 2019) [60]. These botanical treatments may also help in avoiding the side effects associated with synthetic antidepressants by modulating broader cellular pathways (Sun et al., 2022) [61].

Moreover, the neuroimmune mechanisms underlying cytokine-induced depression are gaining attention. The interplay between immune and neural functions is central to the development of depressive symptoms, suggesting that targeting neuroinflammation may offer novel therapeutic strategies (Loftis et al., 2010) [62].

In summary, the neural mechanisms of depression encompass a range of biological processes, including neurotransmitter dysregulation, neurogenesis, and the integrity of neural circuits. Therapeutic implications extend beyond traditional pharmacological approaches to include rapid-acting treatments and botanical medicines, which may offer more effective and holistic strategies for managing this debilitating disorder. Continued research into the molecular underpinnings of depression will be crucial for the development of targeted and personalized therapeutic interventions.

6.2 Psychotherapy and Behavioral Interventions ​

Depression is a complex mental health disorder characterized by various neurobiological alterations, which significantly impact both the brain's structure and function. Recent studies have elucidated several key neural mechanisms underlying depression, providing insights that could inform therapeutic approaches, including psychotherapy and behavioral interventions.

One of the foundational concepts in understanding the neurobiology of depression is the "neurogenesis hypothesis." This hypothesis posits that dysfunctions in neurogenesis, the process by which new neurons are formed, play a critical role in the pathology of major depression. Factors such as stress, neuroinflammation, and oxidative stress have been implicated in the reduction of neurogenesis, particularly in the hippocampus, a brain region essential for mood regulation and cognitive function (Bewernick & Schlaepfer, 2013)[5]. Additionally, alterations in neurotrophic factors, which support neuron growth and survival, are observed in depressed individuals, suggesting a common pathological mechanism between depression and cerebral aging (Bewernick & Schlaepfer, 2013)[5].

Moreover, recent findings indicate that depression is associated with altered connectivity within neural circuits, particularly those governing reward processing. Dysfunction in the reward circuitry, characterized by impaired responses to rewards and punishments, can lead to symptoms such as anhedonia and social withdrawal, which are core features of depression (Fox & Lobo, 2019)[2]. Studies utilizing neuroimaging techniques have shown that these alterations can be linked to imbalances in neurotransmitters, specifically glutamate and GABA, which are crucial for maintaining signal integrity within these circuits (Duman et al., 2019)[59].

The role of stress in the development of depression is also critical. Chronic stress can induce structural and functional changes in key brain regions, including the prefrontal cortex and amygdala, which are involved in emotion regulation and stress responses. These changes are often accompanied by dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, further exacerbating the depressive state (Gold & Wong, 2025)[1]. Importantly, these neurobiological insights suggest that resilience to stress and effective coping mechanisms can mitigate the onset of depression, highlighting the potential for behavioral interventions to enhance resilience and improve mental health outcomes.

Therapeutically, understanding these neural mechanisms opens avenues for both pharmacological and non-pharmacological interventions. Psychotherapy and behavioral interventions can target maladaptive thought patterns and behaviors that exacerbate depression. Cognitive-behavioral therapy (CBT), for example, has been shown to facilitate changes in neural circuitry associated with emotion regulation and reward processing, potentially reversing some of the neurobiological alterations seen in depression (Pan et al., 2025)[63]. Furthermore, integrating exercise as a behavioral intervention has demonstrated promise in improving depressive symptoms, likely through its effects on neuroplasticity and brain structure (Gujral et al., 2017)[7].

In conclusion, the neural mechanisms underlying depression involve complex interactions among neurogenesis, neurotransmitter systems, and stress response pathways. These insights not only enhance the understanding of depression's pathophysiology but also underscore the importance of incorporating psychotherapy and behavioral strategies into treatment paradigms, potentially leading to more effective and individualized therapeutic approaches.

6.3 Future Directions in Treatment Approaches ​

Depression is a multifaceted mental health disorder characterized by a range of symptoms that can significantly impair individual functioning. The neural mechanisms underlying depression involve complex interactions among various neurotransmitter systems, neurobiological pathways, and structural brain changes.

Recent research highlights the role of neurotransmitter imbalances, particularly involving serotonin, norepinephrine, and dopamine, as well as the dysfunction of stress response systems and neural circuits that regulate emotion. These neurobiological underpinnings contribute to the dysregulation observed in individuals with depression [63]. Notably, alterations in the reward circuitry, specifically within the nucleus accumbens and prefrontal cortex, are associated with core depressive symptoms such as anhedonia and motivational deficits [2].

Additionally, chronic stress and depression have been linked to neuroinflammation and neurodegeneration, resulting in atrophy of neurons in cortical and limbic regions. This atrophy is believed to stem from excitotoxic effects related to stress, elevated glucocorticoids, and inflammatory cytokines [59]. Neuroimmune mechanisms are increasingly recognized as central to the development of depressive symptoms, with cytokines influencing neural circuits implicated in mood regulation [62].

Neural plasticity also plays a crucial role in the pathophysiology of depression. Disruptions in neural plasticity, including neurogenesis and synaptic remodeling, have been observed in depressed individuals. These alterations can be reversed through therapeutic interventions, suggesting that enhancing neural plasticity may be a promising target for treatment [8].

Therapeutic implications stemming from these findings include the development of more targeted and personalized treatment approaches. Current antidepressants primarily target monoamine systems but often exhibit delayed efficacy and low remission rates [64]. As such, novel treatment strategies are being explored, including rapid-acting agents that focus on glutamate and GABA systems, which may address the limitations of traditional pharmacotherapy [59].

Future directions in treatment approaches could involve a multi-modal strategy that integrates pharmacological, psychotherapeutic, and lifestyle interventions, such as exercise and acupuncture, which have shown promise in enhancing neuroplasticity and overall mental health [[pmid:29122145][65]. The ongoing exploration of the molecular and cellular mechanisms of depression will likely inform the development of innovative therapies that not only alleviate symptoms but also target the underlying neurobiological dysfunctions, ultimately improving patient outcomes and reducing the burden of this prevalent disorder [3].

7 Conclusion ​

The investigation into the neural mechanisms of depression reveals a complex interplay of neuroanatomical, neurochemical, and genetic factors that contribute to the disorder's pathophysiology. Key findings indicate that alterations in the prefrontal cortex, amygdala, and hippocampus are central to emotional regulation and cognitive function, with dysfunction in neurotransmitter systems such as serotonergic, dopaminergic, and noradrenergic pathways exacerbating depressive symptoms. The role of neuroplasticity, particularly in relation to neurogenesis and synaptic changes, is critical in understanding the persistence of depression. Future research should focus on identifying novel therapeutic targets and biomarkers, as well as developing interventions that address the multifaceted nature of depression. A more integrative approach that combines pharmacological treatments with psychotherapeutic and lifestyle modifications may enhance treatment efficacy and improve patient outcomes, paving the way for innovative strategies in managing this prevalent mental health disorder.

References ​

  • [1] Philip W Gold;Ma-Li Wong. Advances in discerning the mechanisms underlying depression and resiliency: relation to the neurobiology of stress and the effects of antidepressants.. Molecular psychiatry(IF=10.1). 2025. PMID:40263526. DOI: 10.1038/s41380-025-03019-8.
  • [2] Megan E Fox;Mary Kay Lobo. The molecular and cellular mechanisms of depression: a focus on reward circuitry.. Molecular psychiatry(IF=10.1). 2019. PMID:30967681. DOI: 10.1038/s41380-019-0415-3.
  • [3] Donghai Wu;Siying Qu;Haiju Sun;Shuting Zhou;Xinyuan Qu;Yutian Chen;Hantong Hu;Xiaoyu Li. Unveiling the brain mechanism underlying depression: 12 Years of insights from bibliometric and visualization analysis.. Brain research bulletin(IF=3.7). 2025. PMID:39947302. DOI: 10.1016/j.brainresbull.2025.111246.
  • [4] Bokai Wang;Teng He;Guofan Qiu;Chong Li;Song Xue;Yuanjia Zheng;Taiyi Wang;Yucen Xia;Lin Yao;Jinglan Yan;Yongjun Chen. Altered synaptic homeostasis: a key factor in the pathophysiology of depression.. Cell & bioscience(IF=6.2). 2025. PMID:40001206. DOI: 10.1186/s13578-025-01369-y.
  • [5] Bettina H Bewernick;Thomas E Schlaepfer. Chronic depression as a model disease for cerebral aging.. Dialogues in clinical neuroscience(IF=8.9). 2013. PMID:23576891. DOI: .
  • [6] Angela Spirou;Nancy D Chiaravalloti;Ekaterina Dobryakova. Corticostriatal Hyperactivation to Reward Presentation in Individuals With TBI With High Depressive Symptomatology: A Pilot Study.. The Journal of head trauma rehabilitation(IF=3.3). 2019. PMID:31033743. DOI: 10.1097/HTR.0000000000000482.
  • [7] Swathi Gujral;Howard Aizenstein;Charles F Reynolds;Meryl A Butters;Kirk I Erickson. Exercise effects on depression: Possible neural mechanisms.. General hospital psychiatry(IF=3.7). 2017. PMID:29122145. DOI: 10.1016/j.genhosppsych.2017.04.012.
  • [8] Wei Liu;Tongtong Ge;Yashu Leng;Zhenxiang Pan;Jie Fan;Wei Yang;Ranji Cui. The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex.. Neural plasticity(IF=3.7). 2017. PMID:28246558. DOI: 10.1155/2017/6871089.
  • [9] Il Bin Kim;Seon-Cheol Park. Neural Circuitry-Neurogenesis Coupling Model of Depression.. International journal of molecular sciences(IF=4.9). 2021. PMID:33671109. DOI: 10.3390/ijms22052468.
  • [10] Ya-Nan Gao;Yong-Qian Zhang;Hao Wang;Yu-Lin Deng;Nuo-Min Li. A New Player in Depression: MiRNAs as Modulators of Altered Synaptic Plasticity.. International journal of molecular sciences(IF=4.9). 2022. PMID:35562946. DOI: 10.3390/ijms23094555.
  • [11] Christopher G Davey;Michael Breakspear;Jesus Pujol;Ben J Harrison. A Brain Model of Disturbed Self-Appraisal in Depression.. The American journal of psychiatry(IF=14.7). 2017. PMID:28595489. DOI: 10.1176/appi.ajp.2017.16080883.
  • [12] Shuyi Li;Mingzhou Gao;Zijun Mou;Haiyan Zhang;Ying Wang;Yujiao Zhang. Advances in neurotransmitter-mediated prefrontal circuitry in depression.. Progress in neuro-psychopharmacology & biological psychiatry(IF=3.9). 2025. PMID:40848830. DOI: 10.1016/j.pnpbp.2025.111475.
  • [13] Jinzhao Wei;Licong Li;Jiayi Zhang;Erdong Shi;Jianli Yang;Xiuling Liu. Computational Modeling of the Prefrontal-Cingulate Cortex to Investigate the Role of Coupling Relationships for Balancing Emotion and Cognition.. Neuroscience bulletin(IF=5.8). 2025. PMID:38869704. DOI: 10.1007/s12264-024-01246-7.
  • [14] John Myers;Jiayang Xiao;Raissa K Mathura;Ben Shofty;Victoria Gates;Joshua Adkinson;Anusha B Allawala;Adrish Anand;Ron Gadot;Ricardo Najera;Hernan G Rey;Sanjay J Mathew;Kelly Bijanki;Garrett Banks;Andrew Watrous;Eleonora Bartoli;Sarah R Heilbronner;Nicole Provenza;Wayne K Goodman;Nader Pouratian;Benjamin Y Hayden;Sameer A Sheth. Intracranial directed connectivity links subregions of the prefrontal cortex to major depression.. Nature communications(IF=15.7). 2025. PMID:40628743. DOI: 10.1038/s41467-025-61487-6.
  • [15] Silvia Rigucci;Gianluca Serafini;Maurizio Pompili;Giorgio D Kotzalidis;Roberto Tatarelli. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies.. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry(IF=3.8). 2010. PMID:19670087. DOI: 10.1080/15622970903131571.
  • [16] Eydie L Moses-Kolko;Susan B Perlman;Katherine L Wisner;Jeffrey James;A Tova Saul;Mary L Phillips. Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression.. The American journal of psychiatry(IF=14.7). 2010. PMID:20843875. DOI: 10.1176/appi.ajp.2010.09081235.
  • [17] Cedric Fabian Kirstein;Onur Güntürkün;Sebastian Ocklenburg. Ultra-high field imaging of the amygdala - A narrative review.. Neuroscience and biobehavioral reviews(IF=7.9). 2023. PMID:37230235. DOI: 10.1016/j.neubiorev.2023.105245.
  • [18] Udo Dannlowski;Patricia Ohrmann;Carsten Konrad;Katharina Domschke;Jochen Bauer;Harald Kugel;Christa Hohoff;Sonja Schöning;Anette Kersting;Bernhard T Baune;Lena S Mortensen;Volker Arolt;Pienie Zwitserlood;Jürgen Deckert;Walter Heindel;Thomas Suslow. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity.. The international journal of neuropsychopharmacology(IF=3.7). 2009. PMID:18544183. DOI: 10.1017/S1461145708008973.
  • [19] Udo Dannlowski;Patricia Ohrmann;Jochen Bauer;Jürgen Deckert;Christa Hohoff;Harald Kugel;Volker Arolt;Walter Heindel;Anette Kersting;Bernhard T Baune;Thomas Suslow. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2008. PMID:17406646. DOI: 10.1038/sj.npp.1301411.
  • [20] Greg J Siegle;Stuart R Steinhauer;Michael E Thase;V Andrew Stenger;Cameron S Carter. Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals.. Biological psychiatry(IF=9.0). 2002. PMID:11983183. DOI: 10.1016/s0006-3223(02)01314-8.
  • [21] Ying Yang;Jian-Zhi Wang. From Structure to Behavior in Basolateral Amygdala-Hippocampus Circuits.. Frontiers in neural circuits(IF=3.0). 2017. PMID:29163066. DOI: 10.3389/fncir.2017.00086.
  • [22] Il Bin Kim;Seon-Cheol Park. The Entorhinal Cortex and Adult Neurogenesis in Major Depression.. International journal of molecular sciences(IF=4.9). 2021. PMID:34769155. DOI: 10.3390/ijms222111725.
  • [23] Andrea Nieto-Quero;Patricia Chaves-Peña;Luis J Santín;Margarita Pérez-Martín;Carmen Pedraza. Do changes in microglial status underlie neurogenesis impairments and depressive-like behaviours induced by psychological stress? A systematic review in animal models.. Neurobiology of stress(IF=3.6). 2021. PMID:34355047. DOI: 10.1016/j.ynstr.2021.100356.
  • [24] Shaoyi Fang;Zhibin Wu;Yali Guo;Wenjun Zhu;Chunmiao Wan;Naijun Yuan;Jianbei Chen;Wenzhi Hao;Xiaowei Mo;Xiaofang Guo;Lili Fan;Xiaojuan Li;Jiaxu Chen. Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics.. Frontiers in immunology(IF=5.9). 2023. PMID:37881439. DOI: 10.3389/fimmu.2023.1193053.
  • [25] R Crupi;A Marino;S Cuzzocrea. New therapeutic strategy for mood disorders.. Current medicinal chemistry(IF=3.5). 2011. PMID:21861822. DOI: 10.2174/092986711797200417.
  • [26] Eleni Paizanis;Michel Hamon;Laurence Lanfumey. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy.. Neural plasticity(IF=3.7). 2007. PMID:17641737. DOI: 10.1155/2007/73754.
  • [27] Siu W Tang;Daiga Helmeste;Brian Leonard. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review.. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry(IF=3.8). 2012. PMID:22175526. DOI: 10.3109/15622975.2011.639800.
  • [28] Lijin Feng;Hang Xing;Kuo Zhang. The therapeutic potential of traditional Chinese medicine in depression: Targeting adult hippocampal neurogenesis.. Phytomedicine : international journal of phytotherapy and phytopharmacology(IF=8.3). 2022. PMID:35152089. DOI: 10.1016/j.phymed.2022.153980.
  • [29] Arzoo Pannu;Ramesh K Goyal. The Potential Role of Dopamine Pathways in the Pathophysiology of Depression: Current Advances and Future Aspects.. CNS & neurological disorders drug targets(IF=3.0). 2025. PMID:39639477. DOI: 10.2174/0118715273357909241126064951.
  • [30] Chantal Martin-Soelch. Is depression associated with dysfunction of the central reward system?. Biochemical Society transactions(IF=4.3). 2009. PMID:19143654. DOI: 10.1042/BST0370313.
  • [31] Gian Marco Leggio;Salvatore Salomone;Claudio Bucolo;Chiara Platania;Vincenzo Micale;Filippo Caraci;Filippo Drago. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.. European journal of pharmacology(IF=4.7). 2013. PMID:23872400. DOI: 10.1016/j.ejphar.2013.07.022.
  • [32] Eun-Hwa Lee;Pyung-Lim Han. Reciprocal interactions across and within multiple levels of monoamine and cortico-limbic systems in stress-induced depression: A systematic review.. Neuroscience and biobehavioral reviews(IF=7.9). 2019. PMID:30917923. DOI: 10.1016/j.neubiorev.2019.03.014.
  • [33] Sari Goldstein Ferber;Aron Weller;Gal Yadid;Alexander Friedman. Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico-Striatal Loop That Are Implicated in Major Depression.. International journal of molecular sciences(IF=4.9). 2021. PMID:33668515. DOI: 10.3390/ijms22041867.
  • [34] K J Ressler;C B Nemeroff. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.. Depression and anxiety(IF=3.3). 2000. PMID:11098410. DOI: 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4.
  • [35] Kenjiro Seki;Satomi Yoshida;Manoj Kumar Jaiswal. Molecular mechanism of noradrenaline during the stress-induced major depressive disorder.. Neural regeneration research(IF=6.7). 2018. PMID:30028316. DOI: 10.4103/1673-5374.235019.
  • [36] J M Gorman;G Sullivan. Noradrenergic approaches to antidepressant therapy.. The Journal of clinical psychiatry(IF=4.6). 2000. PMID:10703758. DOI: .
  • [37] S A Montgomery. Is there a role for a pure noradrenergic drug in the treatment of depression?. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology(IF=6.7). 1997. PMID:9169305. DOI: 10.1016/s0924-977x(97)00414-8.
  • [38] J M Weiss;R W Bonsall;M K Demetrikopoulos;M S Emery;C H West. Galanin: a significant role in depression?. Annals of the New York Academy of Sciences(IF=4.8). 1998. PMID:9928183. DOI: 10.1111/j.1749-6632.1998.tb10707.x.
  • [39] K J Ressler;C B Nemeroff. Role of norepinephrine in the pathophysiology and treatment of mood disorders.. Biological psychiatry(IF=9.0). 1999. PMID:10560027. DOI: 10.1016/s0006-3223(99)00127-4.
  • [40] Siegfried Kasper;Bruce S McEwen. Neurobiological and clinical effects of the antidepressant tianeptine.. CNS drugs(IF=7.4). 2008. PMID:18072812. DOI: 10.2165/00023210-200822010-00002.
  • [41] Jiuseng Zeng;Ziyu Wang;Xiongwei Zhang;Aotao Zhao;Hu Qi;Yanning Jiang;Dingjun Cai;Nan Zeng. Exploring the neuroplasticity hypothesis in depression: The role of traditional Chinese herbal medicine.. Phytomedicine : international journal of phytotherapy and phytopharmacology(IF=8.3). 2025. PMID:40466510. DOI: 10.1016/j.phymed.2025.156927.
  • [42] Tao Yang;Zheng Nie;Haifeng Shu;Yongqin Kuang;Xin Chen;Jingmin Cheng;Sixun Yu;Huiying Liu. The Role of BDNF on Neural Plasticity in Depression.. Frontiers in cellular neuroscience(IF=4.0). 2020. PMID:32351365. DOI: 10.3389/fncel.2020.00082.
  • [43] Gianluca Serafini. Neuroplasticity and major depression, the role of modern antidepressant drugs.. World journal of psychiatry(IF=3.4). 2012. PMID:24175168. DOI: 10.5498/wjp.v2.i3.49.
  • [44] Harris Eyre;Bernhard T Baune. Neuroplastic changes in depression: a role for the immune system.. Psychoneuroendocrinology(IF=3.6). 2012. PMID:22525700. DOI: 10.1016/j.psyneuen.2012.03.019.
  • [45] Christopher Pittenger;Ronald S Duman. Stress, depression, and neuroplasticity: a convergence of mechanisms.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2008. PMID:17851537. DOI: 10.1038/sj.npp.1301574.
  • [46] Mariagiovanna Cantone;Alessia Bramanti;Giuseppe Lanza;Manuela Pennisi;Placido Bramanti;Giovanni Pennisi;Rita Bella. Cortical Plasticity in Depression.. ASN neuro(IF=3.7). 2017. PMID:28629225. DOI: 10.1177/1759091417711512.
  • [47] Shashikanta Tarai;Rupsha Mukherjee;Sharda Gupta;Albert A Rizvanov;Andras Palotás;V S Chandrasekhar Pammi;Arindam Bit. Influence of pharmacological and epigenetic factors to suppress neurotrophic factors and enhance neural plasticity in stress and mood disorders.. Cognitive neurodynamics(IF=3.9). 2019. PMID:31168328. DOI: 10.1007/s11571-019-09522-3.
  • [48] Christine Heim;Elisabeth B Binder. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics.. Experimental neurology(IF=4.2). 2012. PMID:22101006. DOI: 10.1016/j.expneurol.2011.10.032.
  • [49] Charles B Nemeroff;Wylie W Vale. The neurobiology of depression: inroads to treatment and new drug discovery.. The Journal of clinical psychiatry(IF=4.6). 2005. PMID:16124836. DOI: .
  • [50] Angélica Torres-Berrío;Orna Issler;Eric M Parise;Eric J Nestler. Unraveling the epigenetic landscape of depression: focus on early life stress
.. Dialogues in clinical neuroscience(IF=8.9). 2019. PMID:31949402. DOI: 10.31887/DCNS.2019.21.4/enestler.
  • [51] Ming Li;Xiying Fu;Wei Xie;Wanxu Guo;Bingjin Li;Ranji Cui;Wei Yang. Effect of Early Life Stress on the Epigenetic Profiles in Depression.. Frontiers in cell and developmental biology(IF=4.3). 2020. PMID:33117794. DOI: 10.3389/fcell.2020.00867.
  • [52] Ziqian Cheng;Jingyun Su;Kai Zhang;Huiyi Jiang;Bingjin Li. Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems.. Frontiers in cell and developmental biology(IF=4.3). 2022. PMID:35865627. DOI: 10.3389/fcell.2022.929732.
  • [53] Tiffany C Ho;Lucy S King. Mechanisms of neuroplasticity linking early adversity to depression: developmental considerations.. Translational psychiatry(IF=6.2). 2021. PMID:34628465. DOI: 10.1038/s41398-021-01639-6.
  • [54] Georg Northoff. Gene, brains, and environment-genetic neuroimaging of depression.. Current opinion in neurobiology(IF=5.2). 2013. PMID:22995550. DOI: .
  • [55] Yong-Ku Kim;Byung-Joo Ham;Kyu-Man Han. Interactive effects of genetic polymorphisms and childhood adversity on brain morphologic changes in depression.. Progress in neuro-psychopharmacology & biological psychiatry(IF=3.9). 2019. PMID:29535036. DOI: 10.1016/j.pnpbp.2018.03.009.
  • [56] Signe Penner-Goeke;Elisabeth B Binder. Epigenetics and depression
.. Dialogues in clinical neuroscience(IF=8.9). 2019. PMID:31949407. DOI: 10.31887/DCNS.2019.21.4/ebinder.
  • [57] Xenia Gonda;Gabor Hullam;Peter Antal;Nora Eszlari;Peter Petschner;Tomas Gm Hökfelt;Ian Muir Anderson;John Francis William Deakin;Gabriella Juhasz;Gyorgy Bagdy. Significance of risk polymorphisms for depression depends on stress exposure.. Scientific reports(IF=3.9). 2018. PMID:29500446. DOI: 10.1038/s41598-018-22221-z.
  • [58] Anna Weinberg;Aislinn Sandre. Intergenerational transmission of depression risk and the developing brain.. The American psychologist(IF=7.2). 2024. PMID:39715382. DOI: 10.1037/amp0001482.
  • [59] Ronald S Duman;Gerard Sanacora;John H Krystal. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.. Neuron(IF=15.0). 2019. PMID:30946828. DOI: 10.1016/j.neuron.2019.03.013.
  • [60] Zhengrong Zhang;Taomei Deng;Manli Wu;Aisong Zhu;Guoqi Zhu. Botanicals as modulators of depression and mechanisms involved.. Chinese medicine(IF=5.7). 2019. PMID:31338119. DOI: 10.1186/s13020-019-0246-9.
  • [61] Yilu Sun;Jia Zhao;Jianhui Rong. Dissecting the molecular mechanisms underlying the antidepressant activities of herbal medicines through the comprehensive review of the recent literatures.. Frontiers in psychiatry(IF=3.2). 2022. PMID:36620687. DOI: 10.3389/fpsyt.2022.1054726.
  • [62] Jennifer M Loftis;Marilyn Huckans;Benjamin J Morasco. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.. Neurobiology of disease(IF=5.6). 2010. PMID:19944762. DOI: 10.1016/j.nbd.2009.11.015.
  • [63] Han-Qing Pan;Tian Xia;Yu-Ya-Nan Zhang;Hui-Jie Zhang;Meng-Jie Xu;Jing Guo;Yan Liu;Xue-Ying Bai;Qian Liu;Wei-Zhu Liu;Wen-Hua Zhang;Qi-Gang Zhou;Wei-Hua Yue;Bing-Xing Pan. Unveiling the enigma of anxiety disorders and depression: from pathogenesis to treatment.. Science China. Life sciences(IF=9.5). 2025. PMID:40900421. DOI: 10.1007/s11427-025-3024-y.
  • [64] Sang Won Jeon;Yong-Ku Kim. Molecular Neurobiology and Promising New Treatment in Depression.. International journal of molecular sciences(IF=4.9). 2016. PMID:26999106. DOI: .
  • [65] Peng Li;Jiangna Zhao;Xiuxiang Wei;Longfei Luo;Yuzhou Chu;Tao Zhang;Anning Zhu;Juntao Yan. Acupuncture may play a key role in anti-depression through various mechanisms in depression.. Chinese medicine(IF=5.7). 2024. PMID:39367470. DOI: 10.1186/s13020-024-00990-2.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Depression · Neural Mechanisms · Neurobiology · Neurotransmitters · Genetic Factors

© 2025 MaltSci